NEW YORK, NY / ACCESSWIRE / October 22, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. To determine your eligibility and get free access to our shareholder support tools that provide you with case updates, automated loss calculations and claims recovery assistance, please contact the firm via the links below. There will be no cost or obligation to you.
Ollies Bargain Outlet Holdings, Inc. (NASDAQ: OLLI)
Lawsuit on behalf of: investors who purchased June 6, 2019 - August 28, 2019
Lead Plaintiff Deadline : November 18, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/ollies-bargain-outlet-holdings-inc-loss-form?prid=4016&wire=1
According to the filed complaint, during the class period, Ollies Bargain Outlet Holdings, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company suffered a supply chain issue that impacted the initial inventory available at new stores; (2) as a result, the Company lacked sufficient inventory to meet demand at certain store locations; (3) as a result, the Company's comparable store sales were likely to decrease quarter-over-quarter; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.
Myriad Genetics, Inc. (NASDAQ: MYGN)
Lawsuit on behalf of: investors who purchased September 2, 2016 - August 13, 2019
Lead Plaintiff Deadline : November 26, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/myriad-genetics-inc-loss-form?prid=4016&wire=1
According to the filed complaint, during the class period, Myriad Genetics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Myriad's product, GeneSight, lacked evidence or information sufficient to support the tests in their current form, including their purported benefits; (ii) the U.S. Food and Drug Administration ("FDA") had requested changes to GeneSight and questioned the validity of the test's purported benefits; (iii) Myriad had been in ongoing discussions with the FDA regarding the FDA's requested changes to GeneSight; (iv) Myriad's acquisition of Counsyl-and thereby, Foresight-caused the Company to incur the risk of suffering from lower reimbursement for its expanded carrier screening tests, which had the potential to, and actually did, materialize into a material negative impact on the Company's revenue; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.
Uber Technologies, Inc. (NYSE: UBER)
Lawsuit on behalf of: investors who purchased on behalf of all persons and entities other than Defendants who purchased or otherwise acquired Uber securities pursuant and/or traceable to Uber's registration statement issued in connection with Uber's May 10, 2019 initial public stock offering.
Lead Plaintiff Deadline : December 3, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/uber-technologies-inc-loss-form?prid=4016&wire=1
According to the filed complaint, (1) at the time of the initial public offering, Uber was rapidly increasing subsidies for customer's rides and meals in a bid for market share, which caused the Company's sales and marketing expenses to swell; and (2) Defendants were cutting (or planned to cut) costs in key areas that undermined the Company's central growth opportunities.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE: Levi & Korsinsky, LLP
View source version on accesswire.com: